Turning Defense Into Offense
Nothing blocks a license transaction more than when the target feels that they have a killer noninfringement defense.
Nothing blocks a license transaction more than when the target feels that they have a killer noninfringement defense.
This is definitely a case to watch for those of us who consult with clients on issues around dupes.
We'd love to hear your thoughts. Enter for a chance to win a $250 gift card.
Setbacks, perhaps coupled with jury research that may have suggested that a huge verdict against Moderna was possible, clearly contributed.
What replaced the monolithic IP clause wasn’t chaos. It was structure.
The decline of trial practice opportunities for litigators of all experience levels is something that should be concerning to all of us.
The importance of teamwork in driving successful litigation results can’t be overstated -- especially in complex IP litigation.
Designed to reduce manual docket work by prioritizing what litigators need most: on-demand full docket summarization that explains the whole case to date, followed by on-demand document summaries for filing triage, and AI-powered natural language searching for faster search and retrieval.
The patent litigation market is ever-changing.
Khurram Naik was a major contributor to one of the IP success stories of 2025.
Having a diversified and considered approach to marketing is the best way to spotlight your practice’s unique market offerings.
A patent owner’s statements about the scope of its patents must always be considered carefully.
Takeaways from a Legalweek panel on evolving malpractice risks.
The LF Dealmakers Forum reminds us of the need to stay vigilant, knowledgeable about the rules of the game, and flexible enough to adapt to policy decisions.
The current patent litigation funding market is a lot like a cup of coffee.
The confidential nature of the work done by IP attorneys adds complexity to marketing their achievements.
The report’s presentation of data shows that modern patent litigation remains a vibrant and challenging pursuit for both plaintiffs and defendants.
The introduction of Cologuard after FDA-approval in 2014 has been a gamechanger in colon cancer diagnosis.